Yestar Healthcare Holdings Co Ltd AI Stock Analysis
Want to see HK:2393 full AI Analyst Report?
Yestar Healthcare Holdings Co Ltd (2393) AI Stock Analysis
Yestar Healthcare Holdings Co Ltd
(HKEX:2393)
The score is primarily constrained by shrinking revenue, unstable profitability, and a fragile balance-sheet profile. Improved debt reduction and cash generation offer support, but bearish technical momentum and loss-based valuation keep the overall score low.
Yestar Healthcare Holdings Co Ltd (2393) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 116.58M
- Dividend Yield
- ―
- Average Volume (3M)
- 526.58K
- Price to Earnings (P/E)
- -1.2
- Beta (1Y)
- 0.42
- Revenue Growth
- -28.07%
- EPS Growth
- 47.54%
- Country
- Hong Kong
- Employees
- 400
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
Yestar Healthcare Holdings Co Ltd Business Overview & Revenue Model
Company Description
Yestar Healthcare Holdings Company Limited, an investment holding company, manufactures, distributes, and sells medical imaging products in Mainland China. The company operates in two segments, Imaging Printing Products, and Medical Products and Equi...
How the Company Makes Money
Yestar Healthcare primarily generates revenue by charging customers for services delivered at its medical facilities. Its revenue model is based on service fees paid by patients for (i) medical aesthetic procedures and treatments (such as non-surgica...
Yestar Healthcare Holdings Co Ltd Financial Statement Overview
Summary
Financial performance is weak overall: revenue has contracted sharply and profitability is highly volatile. Reduced debt, restored positive equity, and comparatively resilient recent cash flow provide partial support.
Income Statement
32NegativeBalance Sheet
41NeutralCash Flow
58Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.35B | 1.49B | 2.41B | 2.91B | 2.80B | 4.93B |
| Gross Profit | 278.09M | 266.86M | 399.20M | 512.78M | 397.55M | 848.70M |
| EBITDA | 50.24M | 50.38M | -40.14M | 376.81M | 19.13M | 417.27M |
| Net Income | -83.96M | -75.03M | 921.61M | -13.89M | -992.23M | 3.33M |
Balance Sheet | ||||||
| Total Assets | 1.13B | 1.19B | 1.43B | 3.43B | 3.37B | 4.56B |
| Cash, Cash Equivalents and Short-Term Investments | 194.45M | 256.26M | 151.78M | 251.56M | 418.15M | 751.77M |
| Total Debt | 202.47M | 211.05M | 316.90M | 1.63B | 1.90B | 1.79B |
| Total Liabilities | 712.76M | 780.27M | 921.84M | 3.82B | 3.71B | 3.73B |
| Stockholders Equity | 379.55M | 378.26M | 461.60M | -457.50M | -408.87M | 755.23M |
Cash Flow | ||||||
| Free Cash Flow | 85.09M | 289.40M | -26.45M | 294.22M | -115.58M | 665.55M |
| Operating Cash Flow | 146.19M | 311.31M | 12.72M | 387.67M | -91.73M | 715.22M |
| Investing Cash Flow | -68.07M | -16.97M | 380.42M | -89.82M | -18.72M | -47.67M |
| Financing Cash Flow | -129.21M | -153.52M | -502.63M | -234.37M | -180.86M | -654.20M |
Yestar Healthcare Holdings Co Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2393, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 39.42 is Neutral, neither overbought nor oversold. The STOCH value of 20.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2393.
Yestar Healthcare Holdings Co Ltd Peers Comparison
Overall Rating
HK:161271.1Outperform
HK:169651Neutral
HK:666951Neutral
HK:999645Neutral
HK:250044Neutral- HK:239342Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1612 | 71Outperform | HKD 448.87M | 4.57 | 13.95% | 6.76% | 10.95% | 9.26% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1696 | 51Neutral | HKD 852.38M | 9.51 | 2.40% | 5.22% | 4.57% | -24.35% |
| HK:6669 | 51Neutral | HKD 1.44B | -24.52 | -3.50% | ― | 9.36% | -153.54% |
| HK:9996 | 45Neutral | HKD 2.59B | -15.40 | -7.65% | ― | 21.23% | 36.89% |
| HK:2500 | 44Neutral | HKD 436.60M | -0.79 | -28.24% | ― | -38.15% | 25.70% |
| HK:2393 | 42Neutral | HKD 116.48M | -1.18 | -22.16% | ― | -28.07% | 47.54% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2393 | Yestar Healthcare Holdings Co Ltd | 0.05 | -0.07 | -58.33% | |
| HK:9996 | Peijia Medical Ltd. | 3.83 | -2.31 | -37.62% | |
| HK:6669 | Acotec Scientific Holdings Limited | 4.61 | -9.15 | -66.50% | |
| HK:1612 | Vincent Medical Holdings Limited | 0.68 | -0.14 | -16.97% | |
| HK:1696 | Sisram Medical Ltd. | 1.82 | -2.46 | -57.46% | |
| HK:2500 | Venus Medtech (Hangzhou), Inc. Class H | 0.99 | -1.34 | -57.51% |
Yestar Healthcare Holdings Co Ltd Corporate Events
Yestar Healthcare Swings to Small Interim Loss Despite Higher Gross Profit
Yestar Healthcare reported unaudited interim revenue of RMB661.6 million for the six months ended 30 June 2026, down from RMB802.6 million a year earlier, while gross profit improved to RMB144.8 million from RMB133.7 million as cost of sales declined...
Yestar Healthcare Flags Interim Loss as China Bulk-Buy Schemes Squeeze Medical Product Revenue
Yestar Healthcare warned that it expects to report an unaudited consolidated net loss of at least RMB0.45 million for the six months ended 30 June 2026, a sharp reversal from an unaudited net profit of about RMB11.1 million a year earlier. The compan...
Yestar Healthcare Sets Late-August Board Meeting to Review Interim Results and Potential Dividend
Yestar Healthcare Holdings has scheduled a board meeting for 28 August 2026 to review and approve its unaudited consolidated interim results for the six months ended 30 June 2026. The board will also consider declaring an interim dividend, signaling...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026